DCPH Share Price Performance
US$0
0.00 (0.00%)
Sorry, there is currently no price data for this company.
DCPH Community Narratives
There are no narratives available yet.
Recent DCPH News & Updates
No updates
Deciphera Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Mar 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -2.20
- Gross Margin
- -38.66%
- Net Profit Margin
- -108.87%
- Debt/Equity Ratio
- 0%
Deciphera Pharmaceuticals, Inc. Competitors
About DCPH
- Founded
- 2003
- Employees
- 355
- CEO
- WebsiteView website
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
U.S. Market Performance
- 7 Days: -0.2%
- 3 Months: 12.2%
- 1 Year: 22.4%
- Year to Date: 7.7%
The Communication Services sector gained 3.4% while the market remained flat over the last week. More promisingly, the market is up 22% over the past year. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
This week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond.
Continue reading